Investor and News

Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections.

View All

View all

Contact Investor Relations

Mads Kronborg

Vice President, Investor Relations & Communication

+45 53 54 82 96

mak@evaxion-biotech.com

Subscribe to Investor Email Alerts

Be the first to know about news, milestones and events at Evaxion by subscribing to our investor email alerts.

Required fields denoted by an asterisk ().

Alert type
Event
News

Investor and News

Latest News

Previous events

Upcoming events

Subscribe to Investor Email Alerts